PCa risk calculator now incorporates PCA3https://europeanurology.com/article/S0302-2838(12)00735-X/pdf/Will+Biomarkers+Save+Prostate+Cancer+Screening%3F
« As the authors acknowledge, restriction of the analysis
to Caucasian patients, who may have different germline
predictors of cancer risk than members of other ethnic
groups, is an important potential limitation to clinical
applicability. Another issue, mentioned briefly at the end
of the discussion, is that other approaches to the post–
negative biopsy setting are being developed. Prominent
examples include the use of multiparametric magnetic
resonance imaging (MRI) andMRI-guided biopsy; extendedtemplate
biopsies, often via a transperineal approach; and
analysis of blood and urine levels of emerging biomarkers.
Indeed, the PCa risk calculator developed using data and
specimens from the Prostate Cancer Prevention Trial now
incorporates urinary levels of PCa antigen 3 gene (PCA3)
or blood levels of [–2]proPSA to improve predictions for
both the first biopsy and repeat biopsy settings [7,8].
Developments like these raise the bar of entry for novel
candidate markers, which should be considered explicitly in
the context of this rich emerging experience and literature,
and ideally should be tested head to head in the same
specimen sets.